Project chronology and history

The key stages of the project were numerous, from research to development :

CHARACTERISATION OF C-LTMRS

by Swedish neurophysiologist Dr. Yngve Zotterman. They were until then mainly known to be involved in the pleasant sensations of touch.

1939

CREATION OF THE TEAM « CHRONIC PAIN »

« MOLECULAR AND CELLULAR MECHANISM » by Dr. Aziz Moqrich at the IBDM & Dr. Stéphane Gaillard who joined the team.

2005
-
2006

CHARACTERISATION OF C-LTMRS

2007
-
2010

CONTACT WITH «SATT SUD-EST»

for an innovative treatment against pain

2012

PATENT APPLICATION

for the use of TAFA4 as an antalgic drug.

2013

CREATION OF TAFALGIE THERAPEUTICS

after a meeting with Eric Schettini

2019

CREATION OF THE COMPANY

Tafalgie Therapeutics finalizing the founders’ round table with the arrival of Laurent Labatut and the establishment of a support team

Early
2020

SUB-LICENCE EXPLOITATION AGREEMENT

with « SATT Sud-Est »

Mid
2020

THE NOBEL PRIZE IN PHYSIOLOGY OR MEDECINE

is earned by Prof. Ardem Patapoutian and Prof. David Julius, for their research on temperature- and touch-sensitive receptors.

2021

THE COMPANY ENTERS INTO OPERATION

with pre-clinical studies, R&D activités, regulatory activities, Scientific Advisory Board, and search for financial support

2022

“An unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage »

IASP 2020 – International Association for the Study of Pain

THE PIPELINE

Discover the key milestones in the progress of the Tafalgie project